Showing results (171-180 of 1,092) with videos related to
Sort By:
Pageof 110
European Journal of Pharmacology|April 6, 1993
Effects of the competitive NMDA receptor antagonist, CGP 37849, on anticonvulsant activity and adverse effects of valproate in amygdala-kindled ratsW Löscher, D HönackEuropean Journal of Pharmacology|November 8, 2002
Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesiaAngelika Richter, Wolfgang LöscherDeutsche Medizinische Wochenschrift (1946)|June 18, 2015
[Vaccinations and malaria prophylaxis for international travelers]Martin Alberer, Thomas LöscherEpilepsia|August 23, 2006
Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugsWolfgang Löscher, Dieter SchmidtActa Neurologica Scandinavica|April 12, 2005
Uncontrolled epilepsy following discontinuation of antiepileptic drugs in seizure-free patients: a review of current clinical experienceD Schmidt, W LöscherEpilepsy Research|November 16, 2004
New horizons in the development of antiepileptic drugs: the search for new targetsWolfgang Löscher, Dieter SchmidtThe Journal of Pharmacology and Experimental Therapeutics|June 1, 1991
The novel competitive N-methyl-D-aspartate (NMDA) antagonist CGP 37849 preferentially induces phencyclidine-like behavioral effects in kindled rats: attenuation by manipulation of dopamine, alpha-1 and serotonin1A receptorsW Löscher, D HönackBrain Research|November 28, 1997
MK-801 potentiates antidystonic effects of clozapine but not of haloperidol in mutant dystonic hamstersA Richter, W LöscherEuropean Journal of Pharmacology|May 4, 1999
Gabapentin decreases the severity of dystonia at low doses in a genetic animal model of paroxysmal dystonic choreoathetosisA Richter, W LöscherEpilepsia|December 12, 2001
In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of ratsH Potschka, W LöscherPageof 110